@article{25466753302d4959a84e1e425d8d7c93,
title = "Use of antineoplastic agents in patients with cancer who have HIV/AIDS",
abstract = "Highly active antiretroviral therapy (HAART) has substantially reduced morbidity and mortality of AIDS-related complications in patients with HIV; however, the prevalence of AIDS-defining cancers and non-AIDS-defining cancers has increased. In this Review we discuss the management of HAART pharmacotherapy in relation to cytotoxic chemotherapy or targeted antineoplastic agents. We will review potential pharmacological interactions between antiretroviral and antineoplastic therapies and consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are receiving HAART therapy.",
author = "Rudek, {Michelle A.} and Charles Flexner and Ambinder, {Richard F.}",
note = "Funding Information: All authors are partly supported by a National Cancer Institute grant ( U01 CA 121947 ) to the AIDS Malignancy Consortium, which has facilitated interactions related to this Review. CF is partly supported by National Institute of Allergy and Infectious Disease grants ( U01 AI 069465 and AI 068636 ). Funding Information: CF has received grant support from GlaxoSmithKline; has served on scientific advisory boards for Bristol-Myers Squibb, GlaxoSmithKline, Merck Pharmaceuticals, Tibotec Pharmaceuticals, Boehringer-Ingelheim, Virostatics, and Inhibitex; and has received honoraria from Abbott Laboratories. MAR has received payment for consultancy from Concordia Pharmaceuticals. RFA declared no conflicts of interest. ",
year = "2011",
month = sep,
doi = "10.1016/S1470-2045(11)70056-0",
language = "English (US)",
volume = "12",
pages = "905--912",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd",
number = "9",
}